All In Biotech

Drug Trial Radar · NCT02498418

Study Comparing Rifaximin With Xifaxan 200 mg in Traveler's Diarrhea

A Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter, Bioequivalence Study With Clinical Endpoint Comparing Rifaximin 200-mg Tablets With Xifaxan® 200-mg Tablets in the Treatment of Travelers' Diarrhea

Last checked: Nov 20, 2026Latest source record: Dec 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 739 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

739

Actual

Start

Jan 6, 2016

Primary completion

Feb 28, 2017

Study completion Feb 28, 2017

Sponsor

Lead sponsor
Actavis Inc.Industry
Sponsor type
Industry
First posted
Jul 15, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to demonstrate rifaximin 200 milligrams (mg) tablets (test) and Xifaxan® 200 mg tablets (reference) are clinically bioequivalent with respect to the clinical cure rates when administered 3 times a day (TID) for 3 days in participants with travelers' diarrhea.

Conditions

  • Diarrhea

Interventions

  • RifaximinDrug

    Tablets, generic formulation of the brand product.

  • Xifaxan®Drug

    Tablets, brand product.

  • Placebo TabletDrug

    Placebo tablets in the same image of the generic rifaximin. Has no active ingredient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Achieved Clinical Cure at Test of Cure (TOC) Visit (Within 24 to 72 Hours From the Time of Last Dose): Per-Protocol (PP) PopulationTime frame: TOC visit (Day 5, 6 or 7)
  2. Number of Participants Who Achieved Clinical Cure at TOC Visit (Within 24 to 72 Hours From the Time of Last Dose): Modified Intent-to-Treat (mITT) PopulationTime frame: TOC visit (Day 5, 6 ,or 7)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site 1

    Coral Gables, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.